European Commission Authorizes Coherus' Pegfilgrastim Biosimilar, Udenyca
The product is the first pegfilgrastim biosimilar to be authorized by the European Commission and the first Coherus product to be cleared by a regulatory authority.
Coherus Biosciences announced today that the European Commission (EC) has granted a marketing authorization for its pegfilgrastim biosimilar, CHS-1701, which Coherus plans to sell as Udenyca. The product is the first pegfilgrastim biosimilar to be authorized by the EC and the first Coherus product to be cleared by a regulatory authority.
"Today’s EC approval decision is the first marketing authorization for Coherus, an important step forward in realizing our mission of increasing access to biologic treatments to patients globally,” said Denny Lanfear, president and CEO of Coherus.
“We look forward to the anticipated US approval later this year and to executing on a vigorous launch, supported by our strategic manufacturing partners in the United States, meeting the highest product quality and production reliability standards,” added Vince Anicetti, COO of Coherus.
The authorization, which is valid in all EU member states and in the European Economic Area, follows a positive opinion adopted by the European Medicines Agency’s Committee for Human Use in July 2018.
The authorization of the pegfilgrastim product, referencing Neulasta, is welcome news for the biosimilar developer; in 2017, Coherus experienced a setback for CHS-1701 when it received a Complete Response Letter (CRL) from the FDA. The CRL cited a need for a reanalysis of a subset of samples with a revised immunogenicity assay, as well as for additional manufacturing information. In the wake of the CRL, the company terminated approximately one-third of its staff in order to streamline its operating costs as it worked toward resolving the FDA’s concerns.
In May 2018, Coherus resubmitted its Biologics License Application. The FDA is expected to make its decision on the product in early November 2018.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
